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ABSTRACT
Footprinting experiments for DNase I digests of a 139-base-pair segment
of pBR-322 DNA in the presence of either netropsin or actinomycin D were
carried out. Plots of oligonucleotide concentration as a function of drug
concentration were analyzed to study the enhancement in cleavage rates at '30
sites, accompanying drug binding at other sites. The pattern of enhancements
is not consistent with drug-induced DNA structural changes, but agrees with a
redistribution mechanism involving DNase I. Since the total number of enzyme
molecules per fragment remains unchanged, drug binding at some sites increases
the enzyme concentration at other sites, giving rise to increased cleavage.
The consequences of the redistribution mechanism for analysis of footprinting
experiments are indicated.
INTRODUCTION
Footprinting analysis provides a means of identifying the binding sites
of equilibrium binding drugs and proteins on DNA molecules derived from
natural sources (1-5). The most frequently used probe in footprinting studies
is the endonuclease DNase I. The enzyme not only reports the sites of ligand
binding but, since it is sensitive to local changes in DNA structure, it has
also been used to determine the sites of ligand-induced structural changes in
DNA. These are reflected in enhancements in the DNase I cleavage rate,
appearing as sites on the DNA lattice bind ligand (6-10).
The rate of cleavage by DNase I at a phosphodiester linkage of DNA,
(rate)i, is governed by rate expression (1), where ki is the cleavage rate
constant at the site and [DNaseI]i is the concentration of enzyme at the
(rate)i m ki [DNaseI]. (1)
site. As is evident from (1), an increase in (rate)i (enhancements) can arise
from an increase in ki caused by a ligand-induced DNA structural change
and/or an increase in [DNaseI]i. The latter could be due to a redistribution
of the enzyme on DNA as some sites on the polymer accept ligand. Neither the
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rate expression, nor the fact that simple mass action effects due to enzyme
redistribution can also give rise to enhancements, are commonly noted in
footprinting experiments.
In an effort to uncover the origin of enhancements in drug footprinting
experiments, we carried out a series of DNase I digests of an end-labeled 139-
base-pair segment of pBR-322 DNA in the presence of various amounts of either
the antiviral agent netropsin or the anticancer drug actinomycin D. The
former is a minor-groove binding peptide which does not greatly distort the
DNA helix (11), while the latter is an intercalating agent which, upon
binding, is likely to alter polymer structure (12-14). The autoradiographic
data resulting from the experiments were quantitatively analyzed using micro-
densitometry and ultimately reduced to a series of "footprinting" plots,
showing oligonucleotide concentration as a function of drug concentration
(15-17). The analysis, presented below, revealed that, while the level of
enhancement varied as a function of sequence, the general enhancements could
be largely explained by a drug-induced redistribution of the enzyme on DNA and
were less likely due to modified DNA structure. The consequences of these
observations for detecting DNA structural changes in the footprinting experi-
ment through rate increases, and for quantitative footprinting analysis
leading to the evaluation of binding constants from footprinting data, are
presented and discussed.
MATERIALS AND METHODS
The preparation of the 139-base-pair restriction fragment obtained by
cleavage of pBR-322 DNA using Hind III and Nci I was as previously described
(18). The fragment was end-labeled at position 33 (referenced to the standard
numbering system of pBR-322 DNA) using a[32P]-dATP and reverse transcriptase.
Establishment of sequence was earlier described (18). The calf thymus DNA used
as carrier DNA (Sigma Chemical Co.) was sonicated and its concentration in
base pairs determined optically using E260 - 13.2 mM-1cm-1. The concentra-
tions of netropsin sulfate and actinomycin-D were determined optically using
-296 20.2 and t440 - 24.45 mM-1cm-1 respectively.
The footprinting experiments were conducted as previously described (18).
Digests in the presence of carrier DNA were carried out in a total volume of
8pl which contained a final DNA concentration of '194gM in DNA base pairs:
193I±M in sonicated carrier DNA and '1pM labeled fragment. After addition of a
specified amount of netropsin or actinomycin-D to a buffered medium containing
DNA, the system was allowed to equilibrate for 30 min prior to the addition of
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the enzyme. Digests with DNase I were for 10 min at 37°C in a 50mM Tris-Cl,
8mM MgC12, 2mM CaC12 pH 7.5 buffer. For each drug, 25 different concen-
trations were used in the range, 0 to 3.88 x 10-5M.
The concentration of enzyme used, -0.2 pM, and the length of the digest
time were such that the total amount of fragment cleavage, as measured by the
amount of full length DNA remaining, was <20%. This means that only a few
percent of the cleaved fragments were the result of multiple cuts by the
enzyme. The labeled oligonucleotide products were separated in a 12% denatur-
ing polyacrylamide gel using an in-house developed, thermostated field
gradient electrophoresis device.
Analysis of the autoradiographic data was by linear scanning micro-
densitometry (15,16). From the autoradiographic data, a file consisting of a
peak's number, corresponding to the genomic numbering system for pBR-322 DNA,
and its cross-sectional area was created. The concentration of an oligomer
was plotted as a function of drug concentration for each DNase I cleavage site
in the region 48-110 of the fragment. These "footprinting plots" along with
the summed band areas for all oligomers produced in a given digest formed the
basis of the analysis. In the region 48-'110 on the fragment, single nucleo-
tide resolution was observed. Differences due to errors in gel loading and
digest periods were small, <10% (16).
The concentration of each oligonucleotide was fitted by least squares to
a linear function of total drug concentration, using data for the first 14
netropsin concentrations (or 16 actinomycin concentrations). The slopes
obtained were divided by the intercepts to give relative slopes which were
used in the analysis. Results for cleavage sites showing low correlation
coefficients or low concentrations (intensities) were rejected. For actino-
mycin D the drug concentrations used corresponded to drug binding to only the
strong sites (the initial loading events) on the restriction fragment. The
footprinting plots showed that, at the highest drug concentration, 7.64 PM,
these sites were '50% occupied. For netropsin the highest drug concentration,
6.49 pM, corresponded to nearly complete occupancy of the strong sites with
some binding to the weaker sites on the fragment (actinomycin has a much lower
binding constant than netropsin).
RESULTS
Photographs of the autoradiograms used in the analysis are shown in
Figures 1 and 2. Typical footprinting plots for various sites on the 139-mer
for actinomycin D and netropsin are shown in Figure 3. Strong binding sites
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Figure 1. A photograph of the netropsin autoradiographic data. Lane 1 is the
no enzyme control while lanes 2 and 27 are DNase I digests of the 139-base-
pair fragment in the absence of netropsin. The lane number and drug concen-
tration (uNM) for digests involving drug were: 3, 38.8; 4, 33.0; 5, 28.0; 6,
23.8; 7, 20.3; 8, 17.2; 9, 14.6; 10, 12.4; 11, 10.57; 12, 9.99; 13, 7.64; 14,
6.49; 15, 5.52, 16, 4.69; 17, 3.99; 18, 3.39, 19, 2.88; 20, 2.45; 21, 2.08;
22, 1.77; 23, 1.50; 24, 1.28; 25, 1.09; 26, 0.92. The numbering system
pertaining to sequence is the genomic number system of pBR-322 DNA.
for either drug appear as inhibitions in the rate of cleavage while weak
binding sites exhibit an initial rate increase followed by inhibition. For
sites located between binding sites, both drugs cause rate enhancements, e.g.
site 75 for netropsin and 57 for actinomycin D. The slopes, calculated as
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Figure 2. A photograph of the actinomycin-D autoradiographic data. Lane 1 is
the no-enzyme control while lane 2 is a DNase 1 digest of the 139-base pair
fragment in the absence of drug. The lane numbers and drug concentrations for
lanes 3-26 are as indicated in the caption to Figure 1. The drug concentra-
tion for lane 27 was 0.78 pLM.
outlined in the Materials and Methods Section, are negative for binding sites
and positive for enhancements. They are given in Table I, with standard
deviations as a measure of reliability, and are indicated graphically on the
sequence of the fragment in Figure 4.
Except for anomalously high values for sites adjacent to binding sites,
*the enhancements, as measured by values of positive slopes, are relatively
constant along the polymer. For netropsin the average slope is 0.95 x 0
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Figure 3. Selected footprinting plots obtained from digests involving
netropsin (A, base 59, thymine; B, base 98, thymine; C, base 75, thymine) and
actinomycin-D (D, base 67, thymine; E, base 57, adenine; F, base 74, guanine).
See figure 4 for the sequence of the fragment. The relative change in
oligomer concentrations, x-r, is as defined in reference 16.
M-1. Eliminating temporarily the high values for sites 53 and 64, we have an
average slope of 0.84 x 105M-1 with a mean-square deviation of 0.30. The
average slope for actinomycin D is 0.48 x 105 M-1. Dropping the high slopes
for sites 58 and 73, we have an average slope of 0.35 x 105M-1 with a rms
deviation of 0.22.
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Table I
Slopes and Standard Deviationsa
Netropsin Actinomycin
Standard Standard
Site Slope Deviation Slope Deviation
45
48
50
51
52
53
54
55
56
57
58
59
62
63
64
65
66
67
68
69
71
72
73
75
76
79
80
81
83
85
87
89
90
92
94
95
96
98
99
102
103
106
108
-0.45
-0.76
-0.80
1. 35
2.06
0.93
-1. 31
-1.51
1.49
1.13
1.03
1.12
1. 33
0.91
0.77
0.63
0.55
0.48
0.73
-0.74
-1. 34
-1.40
0.46
0.39
0.76
0.21
0.12
-0.10
0.14
0.21
0.17
0.24
0.16
0.15
0.13
0.14
0.08
0.16
0.13
0.09
0.07
0.13
0.16
0.11
0.07
0.07
0.12
0.12
0.10
0.21
0.72
0.65
0.85
0.35
0.32
0.31
0.36
0.42
0.57
1.50
-0.06
-0.49
-0.48
-0.33
-0.61
-0.81
-0.36
-0.47
-0.50
-0.45
-0.54
1.61
0.51
0.20
0.11
0.10
0.11
0.06
0.07
0.06
0.05
0.07
0.07
0.11
0.05
0.06
0.05
0.06
0.05
0.05
0.06
0.05
0.06
0.05
0.09
0.22
0.09
0.06
0.46
0.20
0.29
0.18
0.17
0.04
0.14
0.00
0.27
-0.30
-0.70
-0.73
-0.77
0.97
0.09
0.05
0.05
0.05
0.04
0.07
0.04
0.05
0.05
0.08
0.07
0.07
0.07
0.10
a * Times 10-5 M
For both drugs, the enhancements immediately adjacent to binding sites
are 2-3 times greater than those associated with sites more remote from
binding. There also seems to be a decrease of slope in going from lower to
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5'-AGCTTTAATGCGGTAGTTTATCACAGTTAAATTGCTAACG
30 * 40 50 60
3'- AAATTACGCCATCAAATAGTGTCAATTTAACGATTGC
2-
ux1 . .+ ++ ++ +
CAGTCAGGCACCGTGTATGAAATCIAACAATGCGCTCATCGT
70 80 90 100 110+ +
Figure 4. The slopes, as defined in the text, for netropsin (+) and actino-
mycin-D (0). The region of inhibition for netropsin and actinomycin D are
indicated as (_) and (.) respectively.
higher site numbers. Since cleavage at any site is measurable only if there
is no cutting between the site and the labeled end of the fragment, multiple
cuts on a fragment would lead to lower intensities at higher site numbers.
However, since we are in the "2single-hit" regime, multiple cuts are
unimportant.
The ratio of drug-blocked sites to free sites on the restriction frag-
ment, associated with the initial loading events, was 0.27 for netropsin and
0.39 for actinomycin D. The sum of the concentrations of all oligoners
produced in a given digest, as determined by microdensitometry, was constant
over the concentration ranges studied for both drugs.
DISCUSSION
In the drug-DNA footprinting experiment, the drug may influence the
cleavage rate by blocking the enzyme from cleaving at certain sites (16,17),
altering DNA structure away from the sites of binding (19,20), or causing
redistribution of the enzyme to regions where no drug binding is occurring.
Alteration of DNA structure can either increase or decrease the cleavage rate
constant at a site, kj, so both inhibitions and enhancements in rates can be
expected. Furthermore, the changes should differ markedly from one site to
the next, and not always extend over the length of DNA expected for a drug
binding site.
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The redistribution of enzyme should lead to increases in the rate of
cleavage associated with all sites not involved in binding. If the total
amount of cleavage on the fragment remains constant as drug loading occurs, as
is the case for both the netropsin and actinomycin D footprinting experiments
reported here, the amount of enzyme on the fragment is also constant. Thus,
drug binding shifts enzyme to unblocked sites, increasing [DNase I]i at these
sites. This mechanism predicts that all unblocked sites will exhibit the same
fractional enhancement, the magnitude of which is related to the fraction of
the total number of enzyme cleavage sites which are blocked by drug.
The footprinting results for both netropsin and actinomycin D show no
significant decreases in cleavage rates at sites where no drug binding is
occurring. Furthermore, the enhancements are relatively constant along the
sequence, the exceptions being for sites immediately adjacent to drug-binding
sites, Figure 4. This suggests that most of the enhancements are not due to
drug-induced structural changes, but rather are caused by a redistribution of
enzyme over the fragment as sites load with drug. A check on this is provided
by the magnitude of the enhancements.
For netropsin, the fractional enhancement, at 6.49 lM drug, for a
relative slope of 0.84 x 105 M-1 is (0.84 x 105M-1) (6.49 x 10-6M) or 0.54.
The level of enhancement expected if all of the strong sites on the fragment
are totally occupied by drug can be calculated from the ratio of blocked to
free sites, i.e. (1-0.27)-1-1.37, giving 37% enhancement. The discrepancy is
due to loading of secondary sites, which is indicated by the leveling off of
the footprinting plot for site 98 (see Fig. 3). To eliminate this, one can
determine the level of enhancement at lower netropsin concentration where only
the primary sites (no secondary sites) have bound drug. For example, at 2.88
pM netropsin, the strong drug sites are -70% occupied, so the predicted
relative intensity is (1- 0.7 x 0.27)-l-1.23 and the enhancement 0.23; the
actual enhancement is (0.84 x 105M-1) (2.88 x 10-6M) - 0.24.
For actinomycin D, the highest drug concentration used was 7.64)IM making
the observed enhancement (0.35 x 105M-1)(7.64 x 10-6M)-0.27 or 27%. The
enhancement calculated from the strong sites which are only half occupied is
(1-0.5 x 0.39)-i or 1.24, ie 24% enhancement. Thus, it appears that simple
mass action effects associated with the enzyme can explain the general level
of enhancement observed in the footprinting experiments involving both drugs.
The enhancements at positions 58, 73, and 108 for actinomycin D, and 53
and 64 for netropsin, are significantly above the level of enhancement which
can be explained by a redistribution mechanism. Since all are adjacent to
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drug binding sites they may be due to altered DNA structure and/or a "stick-
ing" mechanism involving DNase I interacting with bound drug. Since the
enzyme possesses hydrogen bond donor and acceptor sites as well as charged
groups it could hydrogen bond and electrostatically interact with netropsin
and actinomycin D while they are bound to DNA. This would result in local
increases in [DNase IJi adjacent to drug sites, causing increased cleavage in
these regions.
The higher-than-average enhancements in cleavage rates at 48 and 51 and
lower-than-average enhancements at 92 and 95 for actinomycin D may be due to
structural alteration induced by drug binding. However, they may also be
outlying statistical fluctuations around a constant value. Additional foot-
printing studies involving other cleaving agents will be necessary in order to
establish the presence of altered structure at these sites.
The redistribution mechanism has important consequences for quantitative
footprinting experiments leading to the evaluation of binding constants from
footprinting data. The footprinting plots associated with a binding site must
be corrected for the redistribution effect in order to obtain a valid isotherm
for the site. If the ratio of blocked to free cutting sites is small, the
correction will be negligible and the resulting footprinting plots can be
directly used to determine the occupancy of the site. This situation most
readily obtains in DNA-protein footprinting experiments, where, due to high
binding specificity, only a small fraction of the total DNA present may be
blocked from cleavage (21,22). However, if the fragment bearing the protein
binding site is short, the fraction of protein bound sites to free sites will
be significant. In this case accurate quantitative studies will require
correction for redistribution effects. On the other hand, since drugs and
other small ligands exhibit low binding specifities the ratio of blocked to
free sites is generally large. In this case, the footprinting plots must be
corrected for redistribution in order to obtain valid isotherms for the
various binding sites present in the system.
Although the netropsin-DNA interaction has been analyzed using quan-
titative footprinting methods, and drug binding constants as a function of
sequence determined (16,17), actinomycin D has not been studied in this way.
However, from the slope data presented in Table I and shown in Figure 4, the
strong binding sites for the drug are the sequences: 5'43', TGCT (62-65); CGCA
(68-71); TGCG (100-103) and CGCT (102-105), all of which contains the dinucleo-
tide sequence GC. This result is consistent with earlier footprinting
studies (3-5,7) and the large amount of physicochemical data collected on the
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antibiotic (12-14) indicating that the preferred site is GC. Interestingly,
the sequence, GGCA (76-79), which also contains the dinucleotide GC, is only a
weak binding site, Figures 2 and 3. Although further study will be necessary,
the stacking energy associated with the purine-purine sequence, GG, which
precedes the intercalation site, may be the reason why binding at the adjacent
GC site is discouraged.
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